Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 12/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779687 | 0.85 | KDM4E (0.51) | PTGER1ALDH1A1HPGDMRGPRX4KDM4E | |
| SCHEMBL2405617 | 0.80 | PTGER1 (0.56) | PTGER1HPGDTBXA2RMRGPRX4KDM4E | |
| SCHEMBL21044491 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ECTSAL3MBTL1 | |
| SCHEMBL17144290 | 0.79 | PTGER1 (0.54) | PTGER1TBXA2RMRGPRX4KDM4ECTSA | |
| Ammonia Solution, Strong SCHEMBL5380432 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EPPARGL3MBTL1 | |
| SCHEMBL28444872 | 0.78 | KMO (0.64) | MRGPRX4KDM4EL3MBTL1 | |
| SCHEMBL12753454 | 0.78 | HSD11B1 (0.65) | PTGER1ALDH1A1HPGDKDM4ECYP2C9 | |
| SCHEMBL14413176 | 0.78 | PTGER1 (0.81) | PTGER1TBXA2RMRGPRX4PPARGPTGER3 | |
| SCHEMBL5152093 | 0.77 | PTGER1 (0.81) | PTGER1TBXA2RMRGPRX4PPARGPTGER3 | |
| SCHEMBL14413184 | 0.77 | PTGER1 (0.81) | PTGER1TBXA2RMRGPRX4PPARGPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| CN-1444477-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7648971-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1444477-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | PTGER1 636/4885ALDH1A1 1012/4885HPGD 1200/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | PTGER1 636/4885ALDH1A1 1012/4885HPGD 1200/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | PTGER1 636/4885ALDH1A1 1012/4885HPGD 1200/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | PTGER1 636/4885ALDH1A1 1012/4885HPGD 1200/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | PTGER1 636/4885ALDH1A1 1012/4885HPGD 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.